Genetic mutations

GSK acquired Nuvalent, a biotech company with two drugs under FDA review for targeting genetic mutations in lung cancer, for $10.6 billion. Approval decisions for the drugs are expected later this year.

Scientists have developed PerturbFate, a new computational tool that identifies common control hubs shared by hundreds of cancer mutations rather than targeting each mutation individually. The system tracks how different mutations reshape cells over time to reveal convergence points in disease pathways. This breakthrough could transform treatment approaches for cancer, Alzheimer's, and other diseases driven by multiple genetic mutations.